Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email: bcfdn@aol.com  
Bone and Cancer

Clinical Trials

Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved October 1996

Specific Treatments:

meningeal leukemia or lymphocytic lymphoma

Therapeutic Areas

General Information

Elliotts B Solution has been approved as a treatment for meningeal leukemia or lymphocytic lymphoma. Leukemia and lymphomas are two of the main types of childhood cancers.

Side Effects

Adverse reactions may occur with any given intrathecal injection due to the chemotherapy or the technique of intrathecal administration.

Mechanism of Action

Elliotts B Solution is comparable to cerebrospinal fluid in pH, electrolyte composition, glucose content, and osmolarity. Elliotts B Solution maintains the pH of methotrexate sodium and cytarabine closer to physiologic pH and provides a buffer capacity not found in other diluents, such as preservative-free saline.

Literature References

Cradock, J.C., et al. "Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine, and hydrocortisone sodium succinate." American Journal of Hospital Pharmacy (1978); 35:402.

Additional Information

Acute lymphocytic leukemia (ALL) is primarily a childhood leukemia, which accounts for approximately 57% of childhood leukemias. There are approximately 6,000 cases of ALL in the United States annually.

 How To Order Publications:
  Glossary
  FAQ

Information About

Clinical Trials



 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 


  Copyright 2011 - The Bone and Cancer Foundation